VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2022 | The benefits of next-generation BTK inhibitors in CLL

Barbara Eichhorst, MD, University of Cologne, Cologne, Germany, comments on the efficacy and safety profile of next-generation BTK inhibitors such as acalabrutinib, zanubrutinib, and pirtobrutinib in patients with chronic lymphocytic leukemia (CLL). These BTK inhibitors bind to BTK more specifically and cause therefore fewer side effects. In addition, data has shown that pirtobrutinib is active in patients who are resistant to ibrutinib and acalabrutinib. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Dr Eichhorst receives honoraria for presentations and advisory board from several different pharmaceutical companies involved in targeted agents in CLL (Abbvie, BeiGene, BMS, Gilead, Janssen, MSD, Roche).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter